Biliary Stents Market Size, Share, Growth, and Industry Analysis, By Type (Metal Stents,Plastic Stents), By Application (Hospitals,ASC,Others), Regional Insights and Forecast to 2035

Biliary Stents Market Overview

The global Biliary Stents Market size is projected to grow from USD 232.82 million in 2026 to USD 240.74 million in 2027, reaching USD 316.05 million by 2035, expanding at a CAGR of 3.4% during the forecast period.

Global Biliary Stents Market was valued at approximately USD 141.0 million in 2023, with metal stents contributing USD 94.4 million (≈67%) and plastic stents USD 46.6 million (≈33%). The global demand for biliary stents is supported by rising incidence of biliary obstructions, gallstone diseases, and cholangiocarcinoma cases worldwide. Metal stents now lead by value due to extended patency exceeding 6 months, compared with approximately 3 months for plastic stents. North America held about 43.7% share of the total market in 2023, reflecting high intervention volume and early adoption of covered metallic stents. These indicators shape all Biliary Stents Market Reports, Biliary Stents Market Outlook, and Biliary Stents Industry Forecasts aimed at B2B medical device stakeholders.

In the USA, biliary stent usage remains significant, with tens of thousands of procedures performed annually. The U.S. market, valued at USD 316 million in 2017, is expected to exceed USD 474 million by 2025. Each year, about 4,500 cholangiocarcinoma cases are treated using stent insertions. U.S. endoscopy centers lead in adopting covered self-expanding metal stents (cSEMS), supported by strong reimbursement and advanced imaging systems. The U.S. thus anchors the North American Biliary Stents Market Growth, contributing over 40% of global endoscopic biliary stenting procedures.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Metal stents captured around 67% of total global biliary stent revenue in 2023.
• Major Market Restraint: Plastic stents require up to 4.7 re-interventions per patient-year compared with 2.8 for metal stents.
• Emerging Trends: Fully covered metallic stent usage increased 20% in advanced hospitals during 2024.
• Regional Leadership: North America held roughly 44% market share in 2024.
• Competitive Landscape: Top two companies control about 30% of unit shipments worldwide.
• Market Segmentation: Metal stents contributed USD 94.4 million to USD 141 million market value in 2023.
• Recent Development: Four new high-flexibility, drug-eluting biliary stents launched in 2024.

Biliary Stents Market Latest Trends

The latest Biliary Stents Market Trends highlight a shift toward higher-performance metallic and coated stent models. Covered self-expanding metal stents (cSEMS) achieved 92.6% biliary obstruction resolution, about 7.2% higher than plastic stents (85.4%). Drug-eluting coatings to prevent restenosis were integrated in roughly 15% of new metal models by 2024. Anti-reflux valves and flared end designs—intended to prevent migration—appeared in about 25% of new stent designs. Biodegradable stents achieved an estimated 5% share in pilot trials addressing benign strictures. Asia-Pacific witnessed 18% growth in biliary stent demand in 2023, particularly for gallstone and benign obstruction cases. Dual stent placement in malignant hilar strictures represented 10–15% of advanced case interventions. Meanwhile, EUS-guided stenting grew 12% annually in tertiary centers. These product and procedural trends define the technological trajectory for the Biliary Stents Market Growth and the Biliary Stents Market Opportunities through 2030.

Biliary Stents Market Dynamics

DRIVER

"Increasing prevalence of biliary disorders and minimally invasive procedures"

Growing prevalence of biliary disorders and adoption of minimally invasive ERCP procedures drive the market. Over 4,500 new U.S. cholangiocarcinoma cases yearly require stent therapy. Globally, populations aged ≥65 years rose 20% over the past decade, correlating with higher biliary obstruction incidence. Minimally invasive techniques reduce hospitalization from 7 days to 2–3 days. Plastic stents are used in about 30% of benign stricture cases, while metal stents remain dominant for malignant blockages, offering better patency and fewer re-interventions.

RESTRAINT

"High cost, complications, and stent occlusion"

High device cost and re-intervention rates limit market acceleration. Metallic stents are costlier but longer-lasting; plastic stents, cheaper initially, need replacement every 3 months. Plastic stent users undergo an average 4.7 re-interventions annually versus 2.8 for metal stent users. Migration and occlusion complications affect 5–10% of procedures, with regulatory and clinical validation requirements delaying new product launches by 12–24 months. These challenges constrain faster adoption of advanced designs in cost-sensitive markets.

OPPORTUNITY

"Next-generation stents, coating, biodegradable materials"

Drug-eluting, bioabsorbable, and dual-lumen stent designs present clear opportunities. Four new drug-coated biliary stents introduced in 2024 aim to reduce restenosis. Biodegradable stents achieved around 5% pilot penetration. Polymer coatings with antibiotic or antiproliferative agents are featured in 20–25% of new products. Emerging regions—Africa and Latin America—offer cost-driven growth. OEM collaborations for bundled stent-delivery systems enhance procurement efficiency, representing the next frontier in Biliary Stents Market Opportunities.

CHALLENGE

"Clinical validation, reimbursement, and adoption barriers"

Lengthy clinical validation cycles and inconsistent reimbursement frameworks remain key obstacles. Premium stents need 2–3 years of post-market data for validation. In benign strictures, both plastic and metal stents achieve 90–92% success rates, minimizing differentiation. Migration or fracture risk (~10%) and pricing pressures from local manufacturers constrain premium adoption. Delays of 12–24 months for regulatory approval of biodegradable devices further slow commercialization across several countries.

Biliary Stents Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Metal Stents: Metallic self-expandable stents (SEMS) dominated 67% of total revenue in 2023, driven by 6+ month patency and lower failure rates. Covered SEMS account for 30–40% of metal stents, with partially covered models used in the rest. Metal stents deliver roughly 92.6% resolution in malignant cases. They are essential for inoperable malignancies and long-term palliative care. Drug-eluting and anti-migration metal stent designs are becoming standard across major hospitals, securing their leading position in Biliary Stents Market Share.

The Metal Stents segment of the Biliary Stents Market is estimated to reach USD 148.97 million in 2025, capturing nearly 66.2% of the total market share and projected to grow at a CAGR of 3.6% through 2034. Metal biliary stents, particularly self-expandable metallic stents (SEMS), are increasingly preferred for malignant biliary obstruction due to their superior durability, larger lumen, and reduced migration rate compared to plastic alternatives. Their cost-effectiveness over long-term use and strong adoption in cancer care facilities continue to drive segment growth globally.

Top 5 Major Dominant Countries in the Metal Stents Segment

• United States: The United States is projected to account for USD 43.26 million market size in 2025, holding 29.0% of the global Metal Stents segment and growing at a 3.5% CAGR. High prevalence of biliary cancers, improved healthcare infrastructure, and adoption of endoscopic stenting techniques drive its dominance.
• China: China’s Metal Stents segment is valued at USD 28.69 million in 2025, capturing 19.2% market share with a 3.8% CAGR. The country’s market growth is supported by increasing cases of bile duct obstruction and rapid expansion of endoscopic surgery centers.
• Germany: Germany holds USD 17.34 million market size in 2025, accounting for 11.6% share and a 3.4% CAGR. The rise in hepatobiliary malignancies and aging population contributes significantly to higher stent utilization rates.
• Japan: Japan’s Metal Stents segment is projected at USD 15.12 million in 2025, representing 10.1% market share and 3.5% CAGR, supported by growing use of covered and partially covered metallic stents in clinical practice.
• India: India’s Metal Stents segment records USD 11.46 million in 2025, 7.7% market share with a 3.9% CAGR. The demand surge is attributed to better access to endoscopic retrograde cholangiopancreatography (ERCP) services in tertiary hospitals.

Plastic Stents: Accounting for ~33% of market value, plastic stents remain vital for benign and short-term drainage applications. Replaced roughly every 3 months, they are inexpensive and commonly used in 30% of ERCP procedures. They achieve 90–92% success rates in benign cases and are widely adopted in emerging regions. Plastic stents include straight, double pigtail, and side-by-side types. Drug-coated and biodegradable polymer innovations are in development to extend durability and lower occlusion rates.

The Plastic Stents segment of the Biliary Stents Market is anticipated to reach USD 76.19 million in 2025, representing approximately 33.8% of total share and expected to expand at a CAGR of 3.1% through 2034. Plastic stents remain widely used for temporary biliary drainage, particularly in benign biliary strictures and preoperative decompression cases. Their lower initial cost and easy removability make them preferred in short-term treatment procedures, despite shorter patency compared to metallic options.

Top 5 Major Dominant Countries in the Plastic Stents Segment

• United States: The United States holds USD 24.11 million market size in 2025, capturing 31.7% share with a 3.2% CAGR, driven by high procedural volume and extensive outpatient usage for benign biliary conditions.
• China: China’s Plastic Stents segment is valued at USD 13.87 million in 2025, with 18.2% share and 3.3% CAGR, owing to its expanding healthcare accessibility and preference for cost-effective endoscopic interventions.
• Japan: Japan records USD 10.74 million market size in 2025, accounting for 14.1% share and 3.0% CAGR, supported by an increasing number of endoscopic procedures for biliary drainage in elderly patients.
• Germany: Germany achieves USD 8.62 million in 2025, representing 11.3% market share with 3.1% CAGR. High clinical awareness and advanced endoscopic facilities foster growth in plastic stent procedures.
• India: India’s Plastic Stents segment stands at USD 6.75 million in 2025, equal to 8.9% share and 3.4% CAGR, supported by growing use in secondary healthcare institutions for short-term biliary relief.

BY APPLICATION

Hospitals: Hospitals perform about 70–80% of all biliary stenting procedures. Complex malignant obstructions, hilar tumors, and post-surgical leaks are managed in hospital endoscopy suites equipped for ERCP. Hospital environments favor premium metallic or drug-eluting stents and account for the highest repeat purchasing rates. Negotiated supplier contracts ensure bulk procurement and recurring service demand.

The Hospitals segment dominates the Biliary Stents Market, valued at USD 138.62 million in 2025, holding 61.6% of total market share and expanding at a 3.5% CAGR. Hospitals serve as primary centers for advanced endoscopic and palliative biliary stenting procedures due to availability of specialized gastroenterologists and endoscopy units.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: USD 38.92 million in 2025 with 28.1% share and 3.5% CAGR, fueled by strong hospital infrastructure and large patient inflow for malignant biliary obstruction cases.
• China: USD 27.14 million in 2025 with 19.6% share and 3.7% CAGR, driven by rapid healthcare modernization and expansion of tertiary gastroenterology centers.
• Germany: USD 16.93 million in 2025 with 12.2% share and 3.4% CAGR, supported by widespread hospital-based ERCP facilities and high clinical accuracy standards.
• Japan: USD 13.76 million in 2025 with 9.9% share and 3.3% CAGR, reflecting advanced medical device integration in hospital systems.
• India: USD 10.43 million in 2025 with 7.5% share and 3.8% CAGR, led by growing hospital networks and expansion of endoscopic services in urban regions.

Ambulatory Surgical Centers (ASC): ASCs handle 20–25% of biliary stent cases, focusing on minimally invasive, lower-cost interventions. ASC preference for easy-deploy, short-length metallic or plastic stents continues to rise (~15% YoY). Disposable delivery kits and bundled stent systems are increasingly common. ASCs are a fast-growing end-use channel in developed markets, emphasizing outpatient efficiency.

The ASC segment is valued at USD 55.47 million in 2025, representing 24.6% share and projected to grow at a 3.3% CAGR. Growing preference for outpatient biliary procedures and reduced hospital stay durations are driving this segment’s expansion.

Top 5 Major Dominant Countries in the ASC Application

• United States: USD 15.12 million in 2025 with 27.3% share and 3.2% CAGR, supported by high number of outpatient endoscopy centers performing minimally invasive biliary interventions.
• China: USD 11.68 million in 2025 with 21.0% share and 3.5% CAGR, reflecting steady rise in day-care surgical facilities offering endoscopic stenting.
• Germany: USD 8.41 million in 2025 with 15.1% share and 3.1% CAGR, driven by reimbursement support for outpatient biliary interventions.
• Japan: USD 7.02 million in 2025 with 12.6% share and 3.0% CAGR, fueled by growing transition to non-hospital-based endoscopic practices.
• India: USD 5.43 million in 2025 with 9.8% share and 3.6% CAGR, aided by proliferation of specialty outpatient centers in major urban areas

Others: Specialty GI clinics and research institutions comprise 5–10% of global biliary stent placements. They serve benign structures and pediatric cases, often pioneering biodegradable stent trials. Developing nations also rely on mobile or semi-fixed clinics for biliary drainage procedures. This segment allows innovation testing and early adoption of cost-effective or novel designs.

The Others segment, including specialty clinics and diagnostic centers, is estimated to reach USD 31.07 million in 2025, capturinga  13.8% share with a 3.0% CAGR. Increasing private healthcare participation and adoption of advanced stenting tools in specialized clinics drive growth.

Top 5 Major Dominant Countries in the Other Application

• United States: USD 9.32 million in 2025 with 30.0% share and 3.0% CAGR, driven by independent endoscopic units adopting biliary stenting as routine therapy.
• China: USD 7.24 million in 2025 with 23.3% share and 3.2% CAGR, supported by growing private diagnostic centers offering same-day stenting procedures.
• Germany: USD 4.91 million in 2025 with 15.8% share and 2.9% CAGR, driven by adoption of minimally invasive outpatient biliary interventions.
• Japan: USD 4.09 million in 2025 with 13.2% share and 3.0% CAGR, from expanding network of endoscopic diagnostic facilities.
• India: USD 3.15 million in 2025 with 10.1% share and 3.4% CAGR, reflecting higher accessibility to gastrointestinal endoscopy centers in secondary cities.

Biliary Stents Market Regional Outlook

North America remains the dominant regional market (~44% share), followed by Europe (~23–25%) and Asia-Pacific (~25–27%), with MEA showing early-stage growth. These geographic trends underline global procedural and manufacturing concentration for Biliary Stents Market Forecast.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America generated USD 61.6 million in 2023, leading the global market. The U.S. drives this dominance with tens of thousands of annual ERCP-based stent placements. Over 40% of all covered metal stents are deployed in the U.S., where reimbursement structures favor high-end products. Hospitals invest in anti-migration and drug-eluting stents, while R&D hubs across Boston, Minneapolis, and California advance new coating materials. North American adoption rates exceed global averages by 20–25%, reinforcing the region’s role in Biliary Stents Market Growth and Share leadership.

The North America Biliary Stents Market is valued at USD 71.83 million in 2025, holding 31.9% of the total global market share and expected to advance at a 3.3% CAGR through 2034. North America remains one of the most advanced markets for biliary stent technologies due to its high healthcare spending, robust hospital infrastructure, and wide access to modern endoscopic equipment. The region’s dominance is attributed to an increasing number of patients suffering from biliary tract malignancies, gallstones, and obstructive jaundice that require interventional stenting procedures. The growing presence of leading medical device companies and favorable reimbursement policies further encourage adoption across both hospital and outpatient care facilities.

North America - Major Dominant Countries in the Biliary Stents Market

• United States: The United States leads the North American market with an estimated value of USD 55.19 million in 2025, accounting for approximately 76.8% of the regional share and maintaining a 3.4% CAGR. 
• Canada: Canada is projected to reach a market size of USD 7.46 million by 2025, capturing 10.4% of the regional share and registering a 3.2% CAGR.
• Mexico: Mexico’s biliary stents market is valued at USD 4.19 million in 2025, representing a 5.8% regional share with a 3.0% CAGR.
• Panama: Panama’s market is projected at USD 2.81 million in 2025, accounting for 3.9% share and a 3.1% CAGR.
• Costa Rica: Costa Rica holds a market value of USD 2.18 million in 2025, with a 3.0% share and 3.1% CAGR.

EUROPE

Europe’s market, valued at USD 33 million in 2023, is projected to reach USD 47.3 million by 2030, representing about 23–25% share. Metal stents dominate, but demand for advanced polymer stents is rising. Germany, France, and the U.K. lead regional use, with 52% annual growth in home and hospital endoscopy procedures. European health systems emphasize cost-efficiency, enforcing price caps but encouraging volume-driven procurement. The MDR regulatory framework enhances quality and surveillance, making Europe pivotal in early trials and new product certifications.

The Europe Biliary Stents Market is estimated at USD 62.31 million in 2025, accounting for 27.7% of global market share, with an expected CAGR of 3.2% through 2034. Europe continues to be one of the most technologically advanced regions in interventional gastroenterology. High prevalence of cholangiocarcinoma and benign biliary strictures, coupled with the region’s advanced healthcare systems, drives the need for biliary stents. The strong adoption of ERCP (Endoscopic Retrograde Cholangiopancreatography) procedures and supportive reimbursement policies for palliative and preoperative stenting further strengthen the European market outlook.

Europe - Major Dominant Countries in the Biliary Stents Market

• Germany: Germany dominates the European biliary stents market with USD 20.84 million in 2025, representing 33.4% share and a 3.1% CAGR. The country’s leadership is attributed to its well-developed gastroenterology infrastructure, early adoption of covered metallic stents, and high hospital procedure volumes.
• France: France’s market is valued at USD 12.42 million in 2025, accounting for 19.9% regional share and a 3.0% CAGR. The segment benefits from robust national reimbursement policies for endoscopic stent placement and an increasing preference for minimally invasive biliary drainage across both private and public hospitals.
• United Kingdom: The UK holds USD 10.16 million market value in 2025, with a 16.3% share and a 3.0% CAGR. The country’s growing elderly population and increasing cases of biliary obstruction have led to widespread adoption of endoscopic stenting. 
• Italy: Italy’s biliary stents market is estimated at USD 9.01 million in 2025, capturing 14.5% share and growing at a 3.3% CAGR. The increasing patient awareness, adoption of advanced endoscopic devices, and government support for hospital infrastructure upgrades are key growth contributors.
• Spain: Spain’s market is valued at USD 7.85 million in 2025, representing 12.6% share and a 3.2% CAGR. The nation’s hospital-based palliative stenting programs, combined with growing expertise in interventional endoscopy, continue to propel the use of both metal and plastic biliary stents.

ASIA-PACIFIC

Asia-Pacific represents the fastest-growing region, forecast to account for over 27% of global placements by 2030. China, Japan, South Korea, and India dominate case volumes, with China performing tens of thousands of procedures annually. Plastic stents prevail in emerging markets, while Japan and South Korea lead in adopting biodegradable and coated metallic versions. Regulatory clearance times average 6–9 months, and domestic manufacturing partnerships reduce costs by 20%. The region’s rising middle class and hospital expansion programs fuel long-term market opportunities.

The Asia Biliary Stents Market is projected to reach USD 73.16 million in 2025, representing 32.5% of the global share and expected to post the highest CAGR of 3.6% among all regions. Asia’s dominance in the global market is driven by expanding healthcare infrastructure, rising geriatric population, and increased access to endoscopic therapy. Growing investment in public hospitals, the spread of private healthcare networks, and government initiatives to improve early detection of hepatobiliary diseases are strengthening the region’s market. With major manufacturing hubs and growing affordability of medical devices, Asia continues to serve as both a demand and supply center for biliary stents.

Asia - Major Dominant Countries in the Biliary Stents Market

• China: China leads the Asian market with USD 27.63 million in 2025, accounting for 37.8% share and growing at a 3.7% CAGR. Rapid increase in biliary cancer incidence, large patient pool, and advanced gastroenterology facilities are driving market expansion. 
• Japan: Japan’s market size is USD 18.21 million in 2025, representing 24.9% of the regional share and expanding at a 3.4% CAGR. Japan’s technological advancements in stent coating materials, improved biocompatibility, and innovation in flexible delivery systems contribute significantly to market leadership.
• India: India’s biliary stents market is valued at USD 13.21 million in 2025, capturing 18.1% share with the fastest growth at 3.8% CAGR. Expanding urban healthcare facilities, increasing training for endoscopic specialists, and growing adoption of ERCP-based treatments are fueling steady demand.
• South Korea: South Korea’s market stands at USD 8.24 million in 2025, accounting for 11.3% share and 3.5% CAGR. 
• Australia: Australia records USD 5.87 million in 2025, representing 8.0% of the regional share with a 3.3% CAGR. Patient preference for minimally invasive therapies and strong endoscopy networks drive steady market expansion across major healthcare facilities.

MIDDLE EAST & AFRICA

MEA currently holds 5–7% of the total market, led by Saudi Arabia, UAE, and Egypt. These nations are expanding tertiary hospitals with endoscopic stenting facilities. Plastic stents dominate African countries due to affordability, though oncology centers are beginning to use metal alternatives. Annual market growth in some subregions exceeds 10%. Infrastructure upgrades and physician training programs continue to enhance regional penetration. MEA remains a frontier for expansion in Biliary Stents Market Trends and supplier distribution strategies.

The Middle East and Africa Biliary Stents Market is valued at USD 17.86 million in 2025, accounting for 7.9% of the global market share and expanding at a steady 3.0% CAGR. The region’s market growth is supported by healthcare modernization, improving access to tertiary-level hospitals, and rising prevalence of hepatobiliary cancers. Increasing palliative care initiatives, combined with investment in specialized endoscopic centers, are encouraging the adoption of advanced biliary stent devices. Countries in the Gulf region are seeing accelerated growth due to infrastructure investments, while African nations are gradually improving diagnostic and treatment capabilities for bile duct disorders.

Middle East and Africa - Major Dominant Countries in the Biliary Stents Market

• United Arab Emirates (UAE): The UAE’s market is estimated at USD 5.13 million in 2025, representing 28.7% share and growing at 3.0% CAGR. The country benefits from high healthcare spending, increased adoption of endoscopic procedures, and growing numbers of specialized gastroenterology hospitals.
• Saudi Arabia: Saudi Arabia’s market stands at USD 4.28 million in 2025, accounting for 23.9% share and 3.1% CAGR. The expansion of modern healthcare facilities under Vision 2030, coupled with investments in minimally invasive surgery, is driving demand for biliary stents.
• South Africa: South Africa’s biliary stents market is valued at USD 3.26 million in 2025, representing 18.2% share and 2.9% CAGR. The increasing use of biliary stents in palliative cancer care and rising procedural awareness contribute to steady market growth.
• Qatar: Qatar’s market is estimated at USD 2.83 million in 2025, holding a 15.8% share and a 3.1% CAGR. The country’s growing focus on advanced healthcare technology and investments in specialized endoscopy centers enhances its regional presence.
• Egypt: Egypt’s biliary stents market is valued at USD 2.36 million in 2025, accounting for a 13.2% share and 2.8% CAGR. Expansion of tertiary care hospitals, coupled with increasing accessibility to diagnostic endoscopy, fuels the gradual adoption of biliary stenting procedures.

List of Top Biliary Stents Companies

• Abbott Vascular
• Boston Scientific
• Cook Medical
• C. R. Bard
• Medtronic
• Taewoong Medical

Top Two Companies with Highest Share

• Boston Scientific: Holds approximately 12–15% global unit share, leading in covered metallic and drug-eluting biliary stent designs across 60+ nations.
• Cook Medical: Commands around 10–12% global share, recognized for precision-engineered SEMS stents with advanced coating technologies and delivery control systems.

Investment Analysis and Opportunities

Between 2023–2024, global investments of USD 80–100 million targeted biliary stent innovation, coating technology, and delivery systems. Manufacturers expand into Southeast Asia, Africa, and Latin America to capture emerging demand. Localized manufacturing reduces cost up to 20% compared to imports. Pilot biodegradable stent projects—currently 5% penetration—offer early growth opportunities. Partnerships between device and pharma companies advance drug-eluting stent development. Reimbursement advocacy and clinical data highlighting reduced re-interventions (2.8 vs 4.7 per year) strengthen premium adoption. These trends represent prime Biliary Stents Market Opportunities and capital allocation pathways for medtech investors.

New Product Development

In 2024, four new drug-eluting metal stents with antiproliferative coatings were introduced globally. Dual-lumen stents offering drainage plus drug infusion emerged as a design innovation. Fully covered metallic stents with anti-reflux and anti-migration features now make up 25% of models. Biodegradable polymer stents reached 5% share in early clinical trials for benign cases. Stent introducers below 6.0 Fr enable lower trauma insertions and now form 10% of all new delivery devices. Enhanced radiopacity and inbuilt sensors for flow monitoring appeared in experimental prototypes in 2024–2025. These advances underline the innovation curve shaping Biliary Stents Market Insights and product pipeline growth.

Five Recent Developments

• 2023: Comparative studies confirmed plastic stents required 4.7 re-interventions yearly versus 2.8 for metallic types.
• 2024: Fully covered SEMS with anti-migration flared ends introduced for malignant obstruction management.
• 2025: Biodegradable biliary stent prototypes tested successfully in benign stricture pilot studies.
• 2024: Four new drug-eluting metallic stent models launched for cholangiocarcinoma cases with improved tissue response.
• 2025: Sensor-enabled biliary stent for pressure and bile flow monitoring demonstrated at Asian academic trials.

Report Coverage of Biliary Stents Market

The Biliary Stents Market Report offers complete global, regional, and national insights across market size, trends, segmentation, and opportunities. It covers Type (Metal, Plastic) and Application (Hospitals, ASCs, Others) breakdowns. Regional coverage spans North America, Europe, Asia-Pacific, and MEA, detailing growth patterns, innovation, and regulatory environments. Competitive profiles include Boston Scientific, Cook Medical, Abbott Vascular, Medtronic, Taewoong Medical, and C. R. Bard. The report integrates sections on New Product Development, Investment Analysis, Market Dynamics, and Trends, supported by historical data (2018–2023) and forecasts through 2030. Designed for B2B audiences, it serves OEMs, healthcare procurement leaders, and investors seeking strategic intelligence in Biliary Stents Market Analysis and long-term roadmap planning.

Biliary Stents Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 232.82 Billion in 2026
Market Size Value By	USD 316.05 Billion by 2035
Growth Rate	CAGR of 3.4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Metal Stents Plastic Stents By Application : Hospitals ASC Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample